In this study, using two different injury models in two different species, we found that early post-injury treatment with N-Acetyl Cysteine (NAC) reversed the behavioral deficits associated with the TBI. These data suggest generalization of a protocol similar to our recent clinical trial with NAC in blast-induced mTBI in a battlefield setting [1], to mild concussion from blunt trauma. This study used both weight drop in mice and fluid percussion injury in rats. These were chosen to simulate either mild or moderate traumatic brain injury (TBI). For mice, we used novel object recognition and the Y maze. For rats, we used the Morris water maze. NAC was administered beginning 30–60 minutes after injury. Behavioral deficits due to injury in both...
OBJECTIVE The authors\u27 previous studies have suggested that thymosin beta 4 (Tβ4), a major actin-...
Previously, we have demonstrated that nicotinamide (NAm), a neuroprotective soluble B-group vitamin,...
Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-h...
In this study, using two different injury models in two different species, we found that early post-...
We examined the effects of N-acetylcysteine amide (NACA) in the secondary inflammatory response foll...
Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury...
Abstract Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality of...
BACKGROUND: Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battle...
Background: Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battle...
BACKGROUND: There are no drugs presently available to treat traumatic brain injury (TBI). A variety ...
The mechanisms underlying secondary or delayed cell death following traumatic brain injury are poorl...
Mild traumatic brain injury (mTBI) is a significant public health concern, specially characterized b...
There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single dr...
Traumatic Brain Injury (TBI) is a significant civilian health problem. TBI triggers complex changes ...
This goal of this research is to investigate the effectiveness of N-Acetylcysteine and Vitamin C in ...
OBJECTIVE The authors\u27 previous studies have suggested that thymosin beta 4 (Tβ4), a major actin-...
Previously, we have demonstrated that nicotinamide (NAm), a neuroprotective soluble B-group vitamin,...
Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-h...
In this study, using two different injury models in two different species, we found that early post-...
We examined the effects of N-acetylcysteine amide (NACA) in the secondary inflammatory response foll...
Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury...
Abstract Traumatic brain injury (TBI) is one of the most common causes of morbidity and mortality of...
BACKGROUND: Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battle...
Background: Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battle...
BACKGROUND: There are no drugs presently available to treat traumatic brain injury (TBI). A variety ...
The mechanisms underlying secondary or delayed cell death following traumatic brain injury are poorl...
Mild traumatic brain injury (mTBI) is a significant public health concern, specially characterized b...
There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single dr...
Traumatic Brain Injury (TBI) is a significant civilian health problem. TBI triggers complex changes ...
This goal of this research is to investigate the effectiveness of N-Acetylcysteine and Vitamin C in ...
OBJECTIVE The authors\u27 previous studies have suggested that thymosin beta 4 (Tβ4), a major actin-...
Previously, we have demonstrated that nicotinamide (NAm), a neuroprotective soluble B-group vitamin,...
Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-h...